![Johann Gottfried Hengartner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Johann Gottfried Hengartner
Directeur/Membre du Conseil chez
Profil
Johann Gottfried Hengartner is currently a Director at Kenta Biotech AG and a Professor at the Swiss Federal Institute of Technology.
Previously, he worked as a Director at Bachem Holding AG from 2003 to 2014.
He obtained his undergraduate and doctorate degrees from the Swiss Federal Institute of Technology.
Postes actifs de Johann Gottfried Hengartner
| Sociétés | Poste | Début |
|---|---|---|
Kenta Biotech AG
 Kenta Biotech AG BiotechnologyHealth Technology Kenta Biotech AG engages in the research, development, production, and marketing of biotechnological and pharmaceutical products. It also specializes in the discovery and development of monoclonal antibodies for the treatment of life-threatening hospital infections. The company was founded by Alois B. Lang on February 9, 2006 and is headquartered in Zug, Switzerland. | Directeur/Membre du Conseil | - |
Swiss Federal Institute of Technology | Corporate Officer/Principal | 04/03/2010 |
Anciens postes connus de Johann Gottfried Hengartner
| Sociétés | Poste | Fin |
|---|---|---|
| BACHEM HOLDING AG | Directeur/Membre du Conseil | 28/04/2014 |
Formation de Johann Gottfried Hengartner
Swiss Federal Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BACHEM HOLDING AG | Health Technology |
| Entreprise privées | 1 |
|---|---|
Kenta Biotech AG
Kenta Biotech AG BiotechnologyHealth Technology Kenta Biotech AG engages in the research, development, production, and marketing of biotechnological and pharmaceutical products. It also specializes in the discovery and development of monoclonal antibodies for the treatment of life-threatening hospital infections. The company was founded by Alois B. Lang on February 9, 2006 and is headquartered in Zug, Switzerland. | Health Technology |
